Skip to main content

Table 3 Multivariate adjusted risk estimation of different systolic and diastolic blood pressure as well as pulse pressure quartiles for total mortality in total population and those with and without anti-hypertensive medication: Tehran Lipid and Glucose study (1999–2014)

From: Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study

  BP category Model 1 Model 2
  E/N HR (95% CI) p HR (95% CI) p
Total (N = 1448) SBP < 120 41/413 1.01 (0.64–1.58) 0.96 1.05 (0.67–1.64) 0.84
  120 ≤ SBP < 130* 36/260 Ref    Ref   
  130 ≤ SBP < 140 60/253 1.69 (1.12–2.56) 0.013 1.40 (0.92–2.14) 0.11
  SBP ≥ 140 168/522 1.84 (1.28–2.64) 0.001 1.72 (1.19–2.48) 0.004
Treated (N = 399) SBP < 120 12/52 1.55 (0.67–3.62) 0.31 1.79 (0.75–4.26) 0.19
120 ≤ SBP < 130* 10/45 Ref    Ref   
130 ≤ SBP < 140 20/70 1.71 (0.79–3.68) 0.17 1.66 (0.75–3.67) 0.21
SBP ≥ 140 73/232 1.54 (0.79–2.99) 0.2 1.78 (0.9–3.53) 0.1
Untreated (N = 1049) SBP < 120 29/361 0.92 (0.54–1.56) 0.75 0.92 (0.54–1.57) 0.77
120 ≤ SBP < 130* 26/215 Ref    Ref   
130 ≤ SBP < 140 40/183 1.64 (1.0–2.71) 0.049 1.34 (0.81–2.23) 0.25
SBP ≥ 140 95/290 1.88 (1.21–2.91) 0.005 1.81 (1.16–2.83) 0.009
Total (N = 1448) DBP < 80 136/640 1.79 (1.22–2.65) 0.003 1.68 (1.13–2.5) 0.01
  80 ≤ DBP < 85* 32/276 Ref    Ref   
  85 ≤ DBP < 90 40/194 1.85 (1.16–2.96) 0.009 1.78 (1.12–2.85) 0.015
  DBP ≥ 90 97/338 2.66 (1.78–3.98) <0.001 2.77 (1.85–4.15) <0.001
Treated (N = 399) DBP < 80 43/120 2.92 (1.42–6.02) 0.004 2.73 1.3–5.7) 0.008
80 ≤ DBP < 85* 9/76 Ref    Ref   
85 ≤ DBP < 90 12/56 1.99 (0.84–4.74) 0.12 2.02 (0.84–4.88) 0.11
DBP ≥ 90 51/147 3.68 (1.81–7.5) <0.001 4.53 (2.21–9.3) <0.001
Untreated (N = 1049) DBP < 80 93/520 1.47 (0.93–2.33) 0.1 1.41 (0.88–2.26) 0.15
80 ≤ DBP < 85* 23/200 Ref    Ref   
85 ≤ DBP < 90 28/138 1.88 (1.08–3.27) 0.025 1.88 (1.07–3.28) 0.027
DBP ≥ 90 46/191 2.25 (1.36–3.72) 0.001 2.17 (1.3–3.61) 0.003
Total (N = 1448) PP < 39* 28/363 Ref    Ref   
39 ≤ PP < 51 57/382 1.41 (0.9–2.23) 0.13 1.27 (0.8–2.02) 0.3
51 ≤ PP < 65 91/346 1.79 (1.16–2.76) 0.008 1.51 (0.97–2.33) 0.06
PP ≥ 65 129/357 1.94 (1.26–2.97) 0.002 1.71 (1.11–2.63) 0.014
Treated (N = 399) PP < 49* 24/109 Ref    Ref   
49 ≤ PP < 60 28/94 1.27 (0.72–2.22) 0.4 1.29 (0.73–2.28) 0.34
60 ≤ PP < 74 33/99 1.03 (0.6–1.78) 0.9 0.91 (0.52–1.59) 0.76
PP ≥ 74 30/97 0.88 (0.5–1.54) 0.65 0.84 (0.48–1.48) 0.54
Untreated (N = 1049) PP < 39* 18/279 Ref    Ref   
  39 ≤ PP < 48 22/263 0.88 (0.47–1.64) 0.68 0.66 (0.35–1.26) 0.21
  48 ≤ PP < 61 56/256 1.7 (0.99–2.93) 0.05 1.22 (0.7–2.14) 0.48
  PP ≥ 61 94/251 2.18 (1.29–3.69) 0.003 1.83 (1.07–3.12) 0.027
  1. Age was adjusted by considering it as the time-scale
  2. Model 1: Adjusted for sex
  3. Model 2: Adjusted for sex, BMI, prevalent CVD, diabetes, hypercholesterolemia, eGFR, smoking and anti-hypertensive medication (only for the total population)
  4. BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, pp pulse pressure, E/N events/N, HR hazard ratio, CI confidence interval
  5. *Reference intervals